Neyran Kertmen

783 total citations
56 papers, 491 citations indexed

About

Neyran Kertmen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Neyran Kertmen has authored 56 papers receiving a total of 491 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Neyran Kertmen's work include Breast Cancer Treatment Studies (12 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer Risks and Factors (7 papers). Neyran Kertmen is often cited by papers focused on Breast Cancer Treatment Studies (12 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer Risks and Factors (7 papers). Neyran Kertmen collaborates with scholars based in Türkiye, United Kingdom and Cyprus. Neyran Kertmen's co-authors include Kadri Altundağ, Taner Babacan, Furkan Sarici, Zafer Arık, Özge Keskin, Mustafa Solak, Fatma Paksoy Türköz, İbrahim Petekkaya, Sercan Aksoy and Yavuz Özışık and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Supportive Care in Cancer.

In The Last Decade

Neyran Kertmen

49 papers receiving 479 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Neyran Kertmen Türkiye 11 333 150 100 90 52 56 491
Johanna Wassermann France 12 197 0.6× 98 0.7× 83 0.8× 77 0.9× 42 0.8× 41 514
J. Stuart Ferriss United States 15 220 0.7× 107 0.7× 92 0.9× 182 2.0× 46 0.9× 44 734
Toufic Eid Lebanon 11 279 0.8× 131 0.9× 87 0.9× 62 0.7× 65 1.3× 20 520
Joshua P. Kesterson United States 18 235 0.7× 94 0.6× 86 0.9× 190 2.1× 38 0.7× 60 779
Molly Gabel United States 11 265 0.8× 143 1.0× 97 1.0× 45 0.5× 56 1.1× 17 480
Serena Wong United States 18 272 0.8× 110 0.7× 127 1.3× 168 1.9× 42 0.8× 47 786
Eun‐Jung Jung South Korea 16 275 0.8× 114 0.8× 208 2.1× 167 1.9× 20 0.4× 86 823
Kristin Bixel United States 16 254 0.8× 96 0.6× 71 0.7× 155 1.7× 47 0.9× 70 872
Arzu Yaren Türkiye 14 283 0.8× 82 0.5× 138 1.4× 137 1.5× 35 0.7× 51 550
Antonio Di Meglio France 14 382 1.1× 86 0.6× 209 2.1× 59 0.7× 36 0.7× 67 571

Countries citing papers authored by Neyran Kertmen

Since Specialization
Citations

This map shows the geographic impact of Neyran Kertmen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neyran Kertmen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neyran Kertmen more than expected).

Fields of papers citing papers by Neyran Kertmen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neyran Kertmen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neyran Kertmen. The network helps show where Neyran Kertmen may publish in the future.

Co-authorship network of co-authors of Neyran Kertmen

This figure shows the co-authorship network connecting the top 25 collaborators of Neyran Kertmen. A scholar is included among the top collaborators of Neyran Kertmen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neyran Kertmen. Neyran Kertmen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yıldırım, Hasan Çağrı, et al.. (2023). Conus Medullaris Metastasis in a Patient with Triple-positive Breast Cancer. 1(3). 39–41.
2.
Güven, Deniz Can, Hasan Çağrı Yıldırım, Enes Erul, et al.. (2023). Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment. Expert Review of Anticancer Therapy. 23(10). 1049–1059. 5 indexed citations
3.
Güven, Deniz Can, et al.. (2023). KELIM Score Predicts Outcome in Patients with Platinum-Resistant/Refractory Recurrent Ovarian Cancer. Biomarkers in Medicine. 17(7). 379–389. 5 indexed citations
4.
Yıldırım, Hasan Çağrı, et al.. (2022). SMART syndrome: a case report. Acta Neurologica Belgica. 123(3). 1137–1140. 2 indexed citations
5.
Güven, Deniz Can, et al.. (2021). Adjuvant Treatment with Paclitaxel Plus Trastuzumab for Node-Negative Breast Cancer: Real-Life Experience. Future Oncology. 18(3). 323–331. 3 indexed citations
6.
Onur, Mehmet Ruhi, Necla Özer, Yusuf Ziya Şener, et al.. (2021). Sarcopenia and anthracycline cardiotoxicity in patients with cancer. BMJ Supportive & Palliative Care. 13(4). 453–461. 8 indexed citations
7.
Güven, Deniz Can, Taha Koray Şahin, Oktay Halit Aktepe, et al.. (2021). Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality. BMJ Supportive & Palliative Care. 14(e1). e456–e461. 28 indexed citations
8.
Aktepe, Oktay Halit, Fatma Gündoğdu, Kemal Kösemehmetoğlu, et al.. (2021). THSD7A expression: a novel immunohistochemical determinant in predicting overall survival of metastatic renal cell carcinoma treated with targeted therapy. Irish Journal of Medical Science (1971 -). 191(4). 1561–1567. 4 indexed citations
9.
Onur, R., Deniz Can Güven, Salih Aksu, et al.. (2020). 1504O Relationship between sarcopenia and anthracycline related cardiotoxicity in patients with cancer. Annals of Oncology. 31. S932–S932.
10.
Güven, Deniz Can, Taha Koray Şahin, Neyran Kertmen, et al.. (2020). COVID-19 pandemic: changes in cancer admissions. BMJ Supportive & Palliative Care. 14(e1). e376–e379. 26 indexed citations
11.
Güven, Deniz Can, Taha Koray Şahin, Neyran Kertmen, et al.. (2020). 1724P Changes in the outpatient and inpatient clinic admissions during COVID-19 pandemic: Anticipating and mitigating risks for cancer patients. Annals of Oncology. 31. S1011–S1011. 1 indexed citations
12.
Sarici, Furkan, Taner Babacan, Hakan Büyükhatipoğlu, et al.. (2017). Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience.. PubMed. 21(4). 826–831.
13.
Ateş, Öztürk, Taner Babacan, Neyran Kertmen, et al.. (2016). Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.. PubMed. 21(2). 375–81. 7 indexed citations
15.
Büyükhatipoğlu, Hakan, Taner Babacan, Neyran Kertmen, et al.. (2015). A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.. PubMed. 20(1). 22–7. 5 indexed citations
16.
Kertmen, Neyran, Taner Babacan, Özge Keskin, et al.. (2015). Molecular subtypes in patients with inflammatory breast cancer; a single center experience.. PubMed. 20(1). 35–9. 16 indexed citations
17.
Babacan, Taner, Hakan Büyükhatipoğlu, Neyran Kertmen, et al.. (2015). Chemotherapy might not be beneficial in lymph node- negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis.. PubMed. 20(2). 479–86. 2 indexed citations
18.
Kertmen, Neyran, Sercan Aksoy, Mustafa Cengiz, et al.. (2015). Comparison of Three Different Induction Regimens for Nasopharyngeal Cancer. Asian Pacific Journal of Cancer Prevention. 16(1). 59–63. 2 indexed citations
19.
Babacan, Taner, Orhan Efe, Hakan Büyükhatipoğlu, et al.. (2015). Efficacy of Capecitabine Monotherapy as the First-line Treatment of Metastatic HER2-negative Breast Cancer. Tumori Journal. 101(4). 418–423. 8 indexed citations
20.
Keskin, Özge, Sercan Aksoy, Taner Babacan, et al.. (2014). Impact of the obesity on lymph node status in operable breast cancer patients.. PubMed. 18(4). 824–30. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026